An investigator-sponsored clinical trial of DKN-01 in patients with advanced hepatocellular carcinoma (HCC) with activated Wnt signaling.
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2018
At a glance
- Drugs DKN 01 (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms DIAL-1
- 23 Feb 2018 According to a Leap Therapeutics media release, enrollment of first patient is anticipated in 2018.
- 23 Feb 2018 According to a Leap Therapeutics media release, this trial will be conducted at University Medical Center of the Johannes Gutenberg-University Mainz in Germany.
- 19 May 2017 New trial record